微小RNA与肿瘤上皮间质转化

doi:10.3760/cma.j.issn.1673-422X.2014.12.001

摘要/Abstract

摘要： 近年来大量研究显示，微小RNA（miRNA）通过多种信号通路参与肿瘤上皮间质转化（EMT）的各个环节的调控过程，甚至同一种miRNA在不同肿瘤中对EMT的作用也有着显著差异。miRNA在EMT中的多变的角色对肿瘤的发生发展和指导临床有着重要的意义。

关键词: 肿瘤, 微RNAs, 上皮间充质转化

Abstract: In recent years, a lot of researches have shown microRNA (miRNA) involved in every link of epithelialmesenchymal transition(EMT) regulation process through a variety of signaling pathways in tumor; even the same kind of miRNA plays significantly different roles in different tumors, inducing great significance to guide clinic.

Key words: Neoplasms, MicroRNAs, Epithelialmesenchymal transition

韩雪, 李曼. 微小RNA与肿瘤上皮间质转化[J]. 国际肿瘤学杂志, 2014, 41(12): 881-884.

HAN Xue, LI Man. MicroRNAs and epithelial mesenchymal transition in cancer[J]. Journal of International Oncology, 2014, 41(12): 881-884.

参考文献

［1］ Sreekumar R, Sayan BS, Mirnezami AH, et al. MicroRNA control of invasion and metastasis pathways［J］. Front Genet, 2011(2): 58．［2］ Johansson J, Berg T, Kurzejamska E, et al. MiR155mediated loss of C/EBPβ shifts the TGFβ response from growth inhibition to epithelialmesenchymal transition, invasion and metastasis in breast cancer［J］. Oncogene, 2013, 32(50): 56145624. ［3］ Stinson S, Lackner MR, Adai AT, et al. TRPS1 targeting by miR 221/222 promotes the epithelialtomesenchymal transition in breast cancer［J］. Sci Signal, 2011, 4(177): ra41. ［4］ Hwang MS, Yu N, Stinson SY, et al. MiR221/222 targets adiponectin receptor 1 to promote the epithelialmesenchymal transition in breast cancer［J］. PLoS One, 2013, 8(6): e66502. ［5］ Arora H, Qureshi R, Park WY. MiR506 regulates epithelial mesenchymal transition in breast cancer cell lines［J］. PLoS One, 2013, 8(5): 64273. ［6］ Hamada S, Satoh K, Fujibuchi W, et al. MiR126 acts as a tumor sppressor in pancreatic cancer cells via the regulation of ADAM9［J］. Mol Cancer Res, 2012, 10(1): 310. ［7］ Harazono Y, Muramatsu T, Endo H, et al. miR655 is an EMTsuppressive microRNA targeting ZEB1 and TGFBR2［J］. PLoS One, 2013, 8(5): 62757. ［8］ Zheng H, Li W, Wang Y, et al. miR23a inhibits Ecadherin expression and is regulated by AP1 and NFAT4 complex during Fasinduced EMT in gastrointestinalcancer［J］. Carcinogenesis, 2014, 35(1): 173183. ［9］ Hamada S, Satoh K, Miura S, et al. miR197 induces epithelial mesenchymal transition in pancreatic cancer cells by targeting p120 catenin［J］. J Cell Physiol, 2013, 228(6): 12551263. ［10］ Guo S, Xu X, Tang Y, et al. miR15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by downregulating Bmi1 expression［J］. Cancer Lett, 2014, 344(1): 4046. ［11］ Cai ZG, Zhang SM, Zhang H, et al. Aberrant expression of microRNAs involved in epithelialmesenchymal transition of HT29 cell line［J］. Cell Biol Int, 2013, 37(7): 669674. ［12］ Shi L, Jackstadt R, Siemens H, et al. p53induced miR15a/161 and AP4 form a doublenegative feedback loop to regulate epithelialmesenchymal transition and metastasis in colorectal cancer［J］. Cancer Res, 2014, 74(2): 532542. ［13］ Wang SH, Li X, Zhou LS, et al. microRNA148a suppresses human gastric cancer cell metastasis by reversing epithelialtomesenchymal transition［J］. Tumour Biol, 2013, 34(6): 37053712. ［14］ Zhang L, Wang X, Chen P. miR204 down regulates SIRT1 and reverts SIRT1induced epithelialmesenchymal transition, anoikis resistance and invasion in gastric cancer cells［J］. BMC Cancer, 2013, 13: 290. ［15］ Zhou Y, Li Y, Ye J, et al. MicroRNA491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition［J］. Live Int, 2013, 33(8): 12711280. ［16］ Xia H, Ooi LL, Hui KM. MicroRNA216a/217induced epithelial mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer［J］. Hepatology, 2013, 58(2): 629641. ［17］ Chiou GY, Cherng JY, Hsu HS, et al. Cationic polyurethanes short branch PEImediated delivery of Mir145 inhibited epithelialmesenchymal transdiferentiation and can cer stem like properties and in lung adenocarcinoma［J］. J Control Release, 2012, 159(2): 240250．［18］ Zhu C, Li J, Cheng G, et al. MiR154 inhibits EMT by targeting HMGA2 in prostate cancer cells［J］. Mol Cell Biochem, 2013, 379(12): 6975. ［19］ Qu Y, Li WC, Hellem MR, et al. MiR182 and miR203 induce mesenchymal to epithelial transition and selfsufficiency of growth signals via repressing SNAI2 in prostate cells［J］. Int J Cancer, 2013, 133(3): 544555. ［20］ Joglekar MV, Patil D, Joqlekar VM, et al. The miR30 family miRNAs confer epithe1ia1 phenotype to human pancreatic cells［J］. Islets, 2009, 1(2): l37147. ［21］ Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA30a inhibits epithelialto mesenehymal transition by targeting Snail and is downregulated in non small cell lung cancer［J］. Int J Cancer, 2012, 130(9): 20442053．［22］ Huang J, Yao X, Zhang J, et al. Hypoxiainduced downregulation of miR30c promotes epithelialmesenchymal transition in human renal cell carcinoma［J］. Cancer Sci, 2013, 104(12): 16091617. ［23］ Chen J, Li Q, An Y, et al. CEACAM6 induces epithelialmesenchymal transition and mediates invasion and metastasis in pancreatic cancer［J］. Int J Oncol, 2013, 43(3): 877885. ［24］ Gebeshuber CA, Zatloukal K, Martinez J． MiR29a suppresses tristetraprohn, which is a regulator of epithelial polarity and metastasis［J］． EMBO Rep, 2009, 10(4): 400405．［25］ Ru P, Steele R, Newhall P, et al． miRNA29b suppresses prostate cancer metastasis by regulating epithelialmesenchymal transition signaling［J］． Mol Cancer Ther, 2012, 11(5): 11661173. ［26］ Colangelo T, Fucci A, Votino C, et al. MicroRNA130b promotes tumor development and is associated with poor prognosis in colorectal cancer［J］. Neoplasia, 2013, 15(9): 10861099. ［27］ Dong P, Karaayvaz M, Jia N, et al. Mutant p53 gainoffunction induces epithelial mesenchymal transition through modulation of the miR130bZEB1 axis［J］. Oncogene, 2013, 32(27): 32863295.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.